Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's highly successful weight-loss medication, Wegovy, in 87 countries next year. This strategic move occurs as pharmaceutical companies compete for a portion of the global obesity drug market, which is projected to reach $150 billion by the early 2030s.